10 episodes
Research Developments in Atopic Dermatitis Annenberg Center for Health Sciences at Eisenhower
-
- Health & Fitness
Welcome to this activity focusing on new research related to atopic dermatitis presented as posters at the 2020 virtual annual meetings of the American Academy of Dermatology and the American Academy of Allergy, Asthma, and Immunology. The posters focus on new data related to the use of advanced therapies for atopic dermatitis. Beyond discussing the methods and results of each poster, the faculty, Drs. Steven Feldman and Alan Fleischer, Jr., share their views on the implication of the trial results on clinical practice.
-
Introduction and Overview
Welcome to this activity focusing on new research related to atopic dermatitis presented as posters at the 2020 virtual annual meetings of the American Academy of Dermatology and the American Academy of Allergy, Asthma, and Immunology. The posters focus on new data related to the use of advanced therapies for atopic dermatitis. Beyond discussing the methods and results of each poster, the faculty, Drs. Steven Feldman and Alan Fleischer, Jr., share their views on the implication of the trial results on clinical practice. They also discuss new evidence related to the burden of disease experienced by patients and caregivers and intriguing evidence pointing to the heterogeneity of atopic dermatitis.
-
Efficacy and Safety Trends with Continuous Longterm Use of Crisaborole Ointment 2% in Patients with Mild-to-Moderate Atopic Dermatitis
The poster was presented by Dr. Lebwohl and colleagues at the 2020 American Academy of Dermatology virtual annual meeting.
This audio commentary is provided by Dr. Steve Feldman. -
Safety, Efficacy and Pharmacokinetics of Crisaborole Ointment 2% in Infants Age Three to Less Than 24 Months with Mild-to-Moderate Atopic Dermatitis
This poster was presented by Dr. Schlessinger and colleagues at the 2020 American Academy of Dermatology virtual annual meeting.
This overview is provided by Dr. Steve Feldman. -
Association Between an Itch-Free State in Atopic Dermatitis Treated with Ruxolitinib Cream and Systemic Inflammatory Mediators
This poster was presented by Dr. Owens and colleagues at the 2020 American Academy of Dermatology virtual annual meeting.
This overview is provided by Dr. Steve Feldman. -
Dupilumab Treatment for up to Three Years Demonstrates Sustained Efficacy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Liberty AD Adult Open Label Extension
This poster was presented by Dr. Blauvelt and colleagues at the 2020 American Academy of Dermatology virtual annual meeting.
This over is provided by Dr. Steve Feldman. -
Patient-reported Outcome, or PROs, with Abrocitinib Treatment in Patients with Moderate to Severe Atopic Dermatitis
This poster was presented by Dr. Silverberg and colleagues at the 2020 American Academy of Dermatology virtual annual meeting.
This overview is provided by Dr. Alan Fleischer.